PURPOSE: In this study the diagnostic accuracy of orbital octreotide uptake in patients with presumed active Grave's ophthalmopathy (GO) was evaluated. PATIENTS AND METHODS: A prospective study of 23 patients suffering from GO was carried out. Single photon emission computed tomography (SPECT) images were obtained 4 h after iv injection of 3 mCi 111 indium octreotide. The results were correlated with the patients clinical state during a follow-up of 17.5+/-6 months. RESULTS: Octreotide scintigraphy was positive in 15 and negative in 8 cases, 12 patients with positive octreotide scintigraphy underwent immunosuppressive treatment and showed a clinically positive response with regression of symptoms. In three cases the patients refused immunosuppressive treatment. Patients with negative pathologic orbital octreotide uptake did not undergo any treatment. CONCLUSION: Octreotide scintigraphy is a useful tool to determine the activity state of Graves' ophthalmopathy. Since Graves' ophthalmopathy must be treated in the active phase, octreotide scintigraphy should be performed in subacute cases to facilitate the indications for immunosuppressive treatment.
PURPOSE: In this study the diagnostic accuracy of orbital octreotide uptake in patients with presumed active Grave's ophthalmopathy (GO) was evaluated. PATIENTS AND METHODS: A prospective study of 23 patients suffering from GO was carried out. Single photon emission computed tomography (SPECT) images were obtained 4 h after iv injection of 3 mCi 111 indium octreotide. The results were correlated with the patients clinical state during a follow-up of 17.5+/-6 months. RESULTS:Octreotide scintigraphy was positive in 15 and negative in 8 cases, 12 patients with positive octreotide scintigraphy underwent immunosuppressive treatment and showed a clinically positive response with regression of symptoms. In three cases the patients refused immunosuppressive treatment. Patients with negative pathologic orbital octreotide uptake did not undergo any treatment. CONCLUSION:Octreotide scintigraphy is a useful tool to determine the activity state of Graves' ophthalmopathy. Since Graves' ophthalmopathy must be treated in the active phase, octreotide scintigraphy should be performed in subacute cases to facilitate the indications for immunosuppressive treatment.
Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi Journal: Eur J Nucl Med Date: 1993-08
Authors: P T Postema; E P Krenning; R Wijngaarde; P P Kooy; H Y Oei; W A van den Bosch; J C Reubi; W M Wiersinga; H Hooijkaas; T van der Loos Journal: J Clin Endocrinol Metab Date: 1994-12 Impact factor: 5.958
Authors: L Bartalena; C Marcocci; L Chiovato; M Laddaga; G Lepri; D Andreani; G Cavallacci; L Baschieri; A Pinchera Journal: J Clin Endocrinol Metab Date: 1983-06 Impact factor: 5.958
Authors: A Colao; S Lastoria; D Ferone; R Pivonello; P E Macchia; P Vassallo; G Bonavolonta; P Muto; G Lombardi; G Fenzi Journal: J Clin Endocrinol Metab Date: 1998-11 Impact factor: 5.958